Drug Trial Radar · NCT05768529
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Mar 28, 2023
Primary completion
Dec 31, 2028
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a Phase I/II, single-arm, open-label clinical trial, and its primary objective of phase I and phase II is to evaluate the safety and efficacy of U16 Injection in the treatment of relapsed or refractory NHL,respectively.
Conditions
- Relapsed or Refractory Non-Hodgkin's Lymphoma
Interventions
U16Drug
A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered before U16 treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Types, frequency and severity of adverse eventsTime frame: 24 months
- Overall Remission Rate (ORR)Time frame: 3 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.